Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (Patients with melanoma brain metastases are allowed). Here, BRAF is linked to melanoma.